Byetta Linked to Acute Pancreatitis

Six new cases of hemorrhagic or necrotizing pancreatitis have been reported in patients using exenatide injection (Byetta, Amylin Pharmaceuticals, Inc), the US Food and Drug Administration (FDA) advised healthcare professionals today.

Why Should I Report an Adverse Drug Event?

When I was in charge of the postmarketing drug safety program at the US Food and Drug Administration (FDA) in the early 1980s, 1 particular drug report became etched in my memory.

Multidisciplinary Collaboration Needed to Incorporate Genomics Into Clinical Care

Multidisciplinary collaboration is needed to incorporate genomics into clinical care, according to scientists who have launched a new initiative to investigate potential uses of genetic testing in primary care. Their commentary on the topic, published in the July 29 issue of Nature Genetics, addresses the gap between research on gene–disease associations and the use of […]

Have you been selected to participate in the Physician Practice Information survey?

The AMA and more than 70 other organizations are conducting a comprehensive multi-specialty survey of America’s physician practices. The results will be used to positively influence national decision makers to ensure accurate and fair representation for all physicians and patients, and to articulate the challenges of running a practice that provides expert patient care, while […]

Quest Diagnostics Is Named ‘Best Employer For Healthy Lifestyles’

Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health (NBGH), an association of more than 300 large U.S. employers, has presented its 2008 Best Employers for Healthy Lifestyles Gold Award to the company for its HealthyQuest employee wellness program. In its […]

Subject: FDA- MedWatch- Aprotinin Injection (marketed as Trasylol)

Subject: FDA- MedWatch- Aprotinin Injection (marketed as Trasylol)- Patient Enrollment In The Aprotinin Treatment Group Arm of BART Study Stopped MedWatch – The FDA Safety Information and Adverse Event Reporting Program FDA informed healthcare professionals of the Data Safety Monitoring Board's recommendation to stop patient enrollment in the aprotinin treatment group arm of the Blood […]